Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
|
|
- Warren Hill
- 6 years ago
- Views:
Transcription
1 Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura and Taiji Tsukamoto Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Hokkaido, Japan *For reprints and all correspondence: Naoya Masumori, Department of Urology, School of Medicine, Sapporo Medical University, S1W16, Sapporo, Hokkaido, Japan. masumori@sapmed.ac.jp Received March 26, 2010; accepted July 8, 2010 Jpn J Clin Oncol 2011;41(1) doi: /jjco/hyq148 Advance Access Publication 9 August 2010 Objective: To investigate the clinical outcomes of patients who underwent radical cystectomy for bladder cancer at a single institution and compare those who had pt0 specimens with those who had residual cancer. Methods: From January 1990 to December 2006, 186 patients underwent radical cystectomy with or without neoadjuvant chemotherapy for ct2 or higher stage urothelial carcinoma in the bladder in our hospital. We estimated the 5-year disease-free survival, cancer-specific survival and overall survival by the pathological stage. Results: The median follow-up of the 186 patients was 38.5 months (0 194). Of these, 51 received neoadjuvant chemotherapy. For all subjects, the 5-year disease-free survival was 54.9%, cancer-specific survival 61.0% and overall survival 57.1%. Of the 186 patients, 24 (12.9%) had no residual cancer in the bladder specimen at radical cystectomy. Of the 24 patients with pt0, only 1 (4.2%) died of bladder cancer. The 5-year disease-free survival, cancer-specific survival and overall survival rates in patients with pt0 were 96.0%. We found pt0 histology in 11 of the 51 patients (21.6%) with neoadjuvant chemotherapy and in 13 of the 135 patients (9.6%) with radical cystectomy alone (P ¼ 0.047). Conclusions: We demonstrated that the outcomes of patients who underwent radical cystectomy were similar to those in previous reports. Patients with pt0 showed favorable outcomes for disease-free survival, cancer-specific survival and overall survival in our study. However, they should be periodically followed up because pt0 does not always mean cure. Key words: bladder cancer urothelial carcinoma cystectomy chemotherapy pt0 INTRODUCTION Indications for radical cystectomy are muscle-invasive or high-risk non-muscle-invasive bladder cancer. It is reported that 10% of patients who undergo radical cystectomy have no histologically proven residual cancer ( pt0) in the bladder specimen (1,2). Patients have favorable outcomes when they achieve pt0 histology in radical cystectomy specimens. However, there is some controversy over the clinical meaning of pt0 because it was reported that even patients with pt0 had recurrence and their survival did not differ from those with non-muscle-invasive bladder cancer who had radical cystectomy (2). In this context, we tried to determine the clinical outcomes of patients with pt0 who received radical cystectomy, comparing them with those having persistent cancer with the other pathological stages. PATIENTS AND METHODS We retrospectively investigated the clinical outcomes of patients who had radical cystectomy in our institute from January 1990 through December This study included 299 patients who had bladder cancer without distant metastasis at the initial presentation and underwent radical cystectomy with or without neoadjuvant chemotherapy. We excluded 99 patients from the current study, including 36 with a history of or concomitant upper urinary tract urothelial cancer, 29 with positive surgical margins in specimens obtained at radical cystectomy, 32 with non-urothelial carcinoma specimens and 2 with other malignant diseases that were likely to influence their survival. Of the remaining 200 patients, 186 were ct2 or higher and they were subject for this study. # The Author (2010). Published by Oxford University Press. All rights reserved.
2 116 pt0 bladder cancer after radical cystectomy Two cycles of chemotherapy consisting of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) were basically used as neoadjuvant chemotherapy for patients with clinical stage of T2 or higher. We performed radical cystectomy with the standard technique (3) and pelvic lymph node dissection (PLND). The boundaries of PLND were the circumflex iliac vein inferiorly, the genitofemoral nerve laterally, the internal iliac vein or artery medially, and the iliac bifurcation superiorly before August After that time, we extended the dissection area superiorly to the aortic bifurcation. We determined the tumor stage according to the 1997 TNM classification (4). The histopathological evaluation was performed by several pathologists at our hospital. We performed physical examination and studied the hemogram, serum chemistry profiles, chest X-ray or computed tomography (CT) of the lung, and CT of the abdomen and pelvis after radical cystectomy. The follow-up interval was 6 12 months in patients with pt2 or lower without lymph node involvement, and 3 6 months in those with pt3 or higher and/or lymph node involvement. We estimated disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) by the pathological stage using the Kaplan Meier method. The survival time was calculated from the date of radical cystectomy. The log-rank test was used for evaluating the statistical significance in survival. Fisher s exact test was used for comparing the pt0 incidence rate between the two groups. We analyzed the risk ratios for pt0 incidence according to the extent of the disease before radical cystectomy using logistic regression analysis. A P value of,0.05 was regarded as a statistically significant difference. All statistical analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). RESULTS In 90% of the 186 eligible patients, the histopathology of the specimen at transurethral resection of the bladder tumor was pure urothelial carcinoma (Table 1). Only about 10% of radical cystectomy specimens were not pure urothelial carcinoma. Of the 186 patients, 151 were confirmed to have ct2 or higher disease by pathological examination, which demonstrated microscopic invasion of the bladder muscle or prostatic urethra in specimens from transurethral resection of bladder tumors. The others were diagnosed as having ct2 or higher disease by CT and/or magnetic resonance images. Of the 186 patients, 24 (12.9%) had no residual cancer in their radical cystectomy specimens. There was one patient (0.5%) who did not have a residual tumor in the bladder specimen but had lymph node involvement. We categorized this patient into the pnþ group. The incidences of pt0 histology were 25.0% in those with ct2, 1.8% in those with ct3 and 6.5% in those with ct4. Neoadjuvant chemotherapy was done for 51 patients (27.4%) (Table 2). Of the 135 patients who did not have neoadjuvant chemotherapy, the clinical stage corresponded to the pathological stage in 40.7% and understaging of the clinical stage was found in 25.9%. Of the 51 patients with neoadjuvant chemotherapy, 2 received 1 cycle of chemotherapy, 43 two cycles, 4 three cycles and 2 four cycles. We found pt0 histology in 11 of the 51 patients (21.6%) with neoadjuvant chemotherapy and in 13 of the 135 patients (9.6%) without it (Table 2). There was a significant difference (P ¼ 0.047) in the pt0 incidence between patients with and without neoadjuvant chemotherapy. Table 3 shows risk ratios for pt0 incidence according to the disease extent before radical cystectomy. The clinical stage and presence of neoadjuvant chemotherapy were significant factors for pt0 incidence in univariate analysis. However, in multivariate analysis, the clinical stage was the only independent pre-operative factor that was associated with pt0 incidence. Some patients whose pathological stages were higher than pt2 preferred to receive adjuvant chemotherapy. Nineteen patients underwent MVAC adjuvant chemotherapy ( pt3: 5, pt4: 1 and pnþ: 12). The median follow-up time of the 186 patients was 38.5 (0 194) months with pathologically non-muscle invasive disease having a follow-up period of nearly 6 years (Table 1). Of these patients, 68 died of bladder cancer and 13 died of other causes. Of the 24 patients with pt0, only 1patienthadlocalrecurrence,at11monthsfromradical cystectomy. This patient died of bladder cancer at 24 months. The clinical stage of the patient was ct2 and tumor size was.5 cm in diameter. He underwent 4 cycles of MVAC neoadjuvant chemotherapy and the tumor reduction rate was 80% by bidirectional evaluation. For all patients, the 5-year DFS was 54.9%, CSS 61.0% and OS 57.1%. Patients with pt0 histology had significantly higher DFS than those with pt1, pta or ptis, or pt2 histology (Fig. 1). Similar findings were confirmed for CSS and OS. For 186 patients, there were no significant differences in DFS (P ¼ 0.181), CSS (P ¼ 0.722) and OS (P ¼ 0.713) between those with MVAC neoadjuvant chemotherapy and those without it. DISCUSSION It was reported that the understaging rate in patients with ct2 or higher was about 20 50% (5 8). When comparing clinical stage with the pathological stage among patients without neoadjuvant chemotherapy, our understaging rate was similar to other reports. Therefore, we thought our staging was validated. It was reported that the incidences of pt0 were 40% (9,10) inpatientswithmvacneoadjuvantchemotherapy and % in those with radical cystectomy alone (11,12). In the current study, the former incidence was 21.6% and the latter 9.6%. The incidence of pt0 in our patients with radical cystectomy alone was similar to
3 Jpn J Clin Oncol 2011;41(1) 117 Table 1. Patients characteristics Pathological stage Total pt0 pt1 pt2 pt3 pt4 pnþ N Median follow-up Months Range (0 194) (18 192) (2 187) (0 180) (5 194) (2 138) (4 151) Median age Sex Years old Male Female Histopathology at TURBT UC UC. SCC UC. AC Histopathology at cystectomy UC UC. SCC UC. AC UC. SCC. AC No residual ca Clinical stage ct ct ct cnþ TURBT, transurethral resection of bladder tumor; UC, urothelial carcinoma; SCC, squamous cell carcinoma; AC, adenocarcinoma; No residual ca, no residual cancer. Table 2. Clinical stage vs. pathological stage and pt0 rate by treatment arm Pathological stage (n) Total (186) pt0 (24) pt1 (30) pt2 (36) pt3 (34) pt4 (22) pnþ (40) pt0 rate (%) Cystectomy alone (135) ct ct ct cnþ Neoadjuvant MVAC (51) ct ct ct cnþ MVAC, methotrexate, vinblastine, doxorubicin and cisplatin.
4 118 pt0 bladder cancer after radical cystectomy Table 3. Risk ratios for pt0 incidence according to disease extent before radical cystectomy N Univariate analysis Multivariate analysis Risk ratio 95% CI P value Risk ratio 95% CI P value Tumor size (cm), Tumor number Tumor grade G1/ G Primary or recurrent tumor Primary Recurrent Concomitant CIS Absent Present Clinical stage T T , ,0.01 T Nþ Neoadjuvant chemotherapy Absent Present CI, confidence interval; CIS, carcinoma in situ. previous reports. In the Southwest Oncology (SWOG) trial (9), 50% of patients who initially staged ct2 and 30% of those who staged ct3 or ct4 achieved pt0 by neoadjuvant chemotherapy. Although there was a significant difference in the pt0 incidence between patients with neoadjuvant chemotherapy and those without it in our study, the pt0 incidence in patients staged ct3 seemed to be somewhat lower than that in SWOG. The cycle of MVAC, extension of transurethral resection of bladder cancer and other factors may have been involved in the difference. There have been few reports that discussed the association between tumor status before radical cystectomy and pt0 incidence. We found that the pt0 incidence rate was significantly higher in patients with ct2 than in those with ct3 or ct4. Although neoadjuvant chemotherapy was significantly associated with pt0 incidence in univariate analysis, it was not in multivariate analysis. We considered that this result was related to the low pt0 incidence rate in ct3 in this study. There are some reports that the prognosis of pt0 bladder cancer is favorable. In SWOG, 85% of the patients with pt0 were alive at 5 years after randomization. Although 1 of the 24 patients with pt0 had recurrence and died of bladder cancer in our study, the others had good outcomes: the 5-year DFS and CSS rates were 96%. Volkmer et al. (12) andchoetal.(13) reported that they did not experience local recurrence in patients with pt0. Meanwhile, Kassouf et al. (14) experiencedthreecases (2.5%) of local recurrence in their large volume study. It was local recurrence that we experienced in the one patient with pt0 who died in our series. The original tumor size of the patient seemed to be related to the recurrence because it was.5 cm in diameter. Cheng et al. (15) found,fort2 bladder cancer, that patients with a tumor diameter of,3 cm had a favorable prognosis. In Japan, there are few reports about the prognosis of patients with pt0 bladder cancer from a single institute. There was a limitation because our study design was
5 Jpn J Clin Oncol 2011;41(1) 119 Figure 1. Kaplan Meier curves show disease-free survival (A), cancer-specific survival (B) and overall survival (C) by the pathological stage. retrospective. However, we found favorable outcomes in patients with pt0 bladder cancer that were similar to those in previous reports. Although the clinical outcome of patients with pt0 was better than that of patients with other stages, they should be periodically followed because pt0 does not always mean cure. CONCLUSIONS The outcomes of patients who underwent radical cystectomy in this study were similar to those in previous reports. DFS, CSS and OS in patients with pt0 bladder cancer were better than those with non-pt0. Funding This work was supported by Gohtaro Sugawara-Memorial Research Fund for Urologic diseases. The sponsor of the study had no role in the study design, collection, analysis and interpretation of data.
6 120 pt0 bladder cancer after radical cystectomy Conflict of interest statement None declared. References 1. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165: Thrasher JB, Frazier HA, Robertson JE, Paulson DF. Does a stage pt0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 1994;152: Whitmore WF, Jr. Management of invasive bladder neoplasms. Semin Urol 1983;1: Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors. 5th edn. New York: Wiley, Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145: Ghoneim MA, el-mekresh MM, el-baz MA, el-attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997;158: Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007;51:137 49; discussion Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005;95: Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. NEnglJ Med 2003;349: Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. JClin Oncol 2001;19: Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19: Volkmer BG, Kuefer R, Bartsch G, Jr, Straub M, de Petriconi R, Gschwend JE, et al. Effect of a pt0 cystectomy specimen without neoadjuvant therapy on survival. Cancer 2005;104: Cho KS, Seo JW, Park SY, Cho NH, Choi YD, Yang SC, et al. The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy. Urol Int 2008;81: Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 2007;52: Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Scherer BG, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000;88:
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationLymphadenectomy with Cystectomy: Is It Necessary
European Urology European Urology 46 (2004) 457 461 Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent? Mohamed A. Ghoneim *, Hassan Abol-Enein Urology & Nephrology Center, Gomhouria
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/96833
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationYASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
More informationRadical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
EUROPEAN UROLOGY 61 (2012) 1039 1047 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationA Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density
Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma
More informationImpact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy
www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationOptimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder
Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationComparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationmodels; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.
; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationNeoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More information346
EXTENDED LYMPHADENECTOMY IN BLADDER CANCER DURING RADICAL CYSTECTOMY: BENEFIT AND MORBIDITY Islam Mohiedden M, Diab El-Sayed M, Reda Mohamed S, Saad A M Al Qady, Department of Urology, Zagazig University,
More informationDisease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy
European Urology European Urology 41 2002) 440±448 Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy JuÈrgen E. Gschwend a,b,*, Philipp Dahm c, WilliamR.
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationHydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series
european urology 51 (2007) 690 698 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only
More informationDoes the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study
EUROPEAN UROLOGY 60 (2011) 572 577 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer
More informationPrimary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature
ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T
More informationRefining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Stephen H. Culp,*, Rian J. Dickstein,*, H. Barton Grossman, Shanna M. Pretzsch,* Sima Porten,* Siamak Daneshmand, Jie Cai,*
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationConclusions. Keywords
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,
More information1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013
Advances in Urology Volume 2013, Article ID 317190, 6 pages http://dx.doi.org/10.1155/2013/317190 Research Article Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationLymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
More informationCould salvage surgery after chemotherapy have clinical impact on cancer survival of patients with
Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Kensuke Bekku, Takashi Saika, Yasuyuki Kobayashi, Ryo Kioshimoto, Taiki
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationRadical Cystectomy for Invasive Bladder Cancer: Results of Multiinstitutional
Jpn J Clin Oncol 2004;34(1)14 19 Radical Cystectomy for Invasive Bladder Cancer: Results of Multiinstitutional Pooled Analysis Atsushi Takahashi 1, Taiji Tsukamoto 1, Ken-ichi Tobisu 2, Nobuo Shinohara
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationEUROPEAN UROLOGY 64 (2013)
EUROPEAN UROLOGY 64 (213) 37 313 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationBACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates
2181 Treatment Options for Muscle-invasive Urothelial Cancer for Patients Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Report
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More informationORIGINAL ARTICLE. Willemien Beukers & Titia Meijer & Cornelis J. Vissers & Joost L. Boormans & Ellen C. Zwarthoff & Geert J. L. H.
Virchows Arch (2012) 461:149 156 DOI 10.1007/s00428-012-1277-0 ORIGINAL ARTICLE Down-staging (
More informationTakuya Koie Chikara Ohyama Hayato Yamamoto Atsushi Imai Shingo Hatakeyama Takahiro Yoneyama Yasuhiro Hashimoto Tohru Yoneyama Yuki Tobisawa
Med Oncol (2014) 31:949 DOI 10.1007/s12032-014-0949-9 ORIGINAL PAPER Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with
More informationLymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationTCC recurrence within the upper tract urothelium following
Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationORIGINAL ARTICLE. World J Urol (2011) 29: DOI /s
World J Urol (2011) 29:487 494 DOI 10.1007/s00345-011-0645-8 ORIGINAL ARTICLE Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No.51), pp: 89228-89235 Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma Haichao
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationSecond transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study
Japanese Journal of Endourology(2018)31:108-112 Original Article CJapanese Society of Endourology 2018 Tetsuya Shindo Naotaka Nishiyama Naoya Masumori Second transurethral resection against Ta high grade
More informationOrgan-sparing treatment of invasive transitional cell bladder carcinoma
Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationBJUI. Study Type Therapy (RCT) Level of Evidence 1b
; 2010 Urological Oncology MIXED HISTOLOGY AND NEOADJUVANT CHEMOTHERAPY RESPONSE SCOSYREV ET AL. BJUI Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationImpact of Histologic Variants of Bladder Cancer on Oncology Outcome After Radical Cystectomy
Korean J Urol Oncol 2017;15(3):121-130 https://doi.org/10.22465/kjuo.2017.15.3.121 Original Article Impact of Histologic Variants of Bladder Cancer on Oncology Outcome After Radical Cystectomy Jae Hyeon
More informationBladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationImpact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer
european urology 52 (2007) 1106 1114 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationUrothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis
Pathology Report With Squamous Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis Yunguang Liu, MD, PhD, Marilyn M. Bui, MD, and Bo Xu, MD, PhD Background: Squamous differentiation occurs
More informationAnterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience
DOI 10.1186/s40064-015-1200-7 RESEARCH Open Access Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience Nozomi Hayakawa 1,2*, Nobuyuki Kikuno 1,2, Hiroki
More informationRole of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review
www.kjurology.org DOI:10.4111/kju.2010.51.6.371 Review Article Role of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review Ja Hyeon Ku Department of Urology, Seoul National University
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationBJUI. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer
BJUI BJU INTERNATIONAL Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer Hamed Ahmadi, Anirban P. Mitra *, George
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationNomura et al. BMC Urology (2015) 15:53 DOI /s
Nomura et al. BMC Urology (2015) 15:53 DOI 10.1186/s12894-015-0040-7 RESEARCH ARTICLE Dual-specificity tyrosine phosphorylationregulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder
More informationQuality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy
Original Article Quality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy Guru Sonpavde, MD 1 ; Bryan H. Goldman,
More informationNeoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment of Muscle Invasive Bladder Cancer
Med. J. Cairo Univ., VoL 81, No. 2, March: 117-122, 2013 www.medicaljournalofcairouniversity.com Neoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationInvasive Bladder Transitional Cell Carcinoma OBJECTIVES
Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder
More informationDevelopment and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy
Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy Giuseppe Simone, Marco Bianchi, Diana Giannarelli, Siamak Daneshmand, Rocco
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationOde to a node Lymph node dissec3on in prostate and bladder cancer
5/26/10 Ode to a node Lymph node dissec3on in prostate and bladder cancer Anthony Koupparis 1 Introduc3on prostate cancer PLND most accurate and reliable staging method for LNI Imaging techniques have
More informationEfficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder
www.kjurology.org DOI:10.4111/kju.2010.51.8.525 Urological Oncology Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder Jaewoo Cheon, Hyunchul
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationTURBT for Treatment of Recurrent High Risk Superficial or Muscle-Invasive Bladder Tumours: Factors Contributing to T0 Radical Cystectomy Specimens
Archives of Urology Volume 1, Issue 1, 2018, PP: 9-16 TURBT for Treatment of Recurrent High Risk Superficial or Muscle-Invasive Bladder Tumours: Factors Sz. Lukacs¹, G. Athanasiadis¹, N. Gibbons¹, D. Hrouda¹,
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationThe Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival
with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease
More informationRisk factors for lymph node metastasis in histologically poorly differentiated type early gastric cancer
498 Original article Risk factors for lymph node metastasis in histologically poorly differentiated type early gastric cancer Authors C. Kunisaki 1, M. Takahashi 2, Y. Nagahori 3, T. Fukushima 3, H. Makino
More information